Cost-effectiveness of empagliflozin in heart failure patients irrespective of ejection fraction in England

AIMS: Heart failure (HF) is a complex syndrome commonly categorized into two main phenotypes [left ventricular ejection fraction (LVEF) below or above 40%], and although empagliflozin is the first approved medication with proven clinical effectiveness for both phenotypes, its cost-effectiveness of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Kolovos, Spyros, Bellanca, Leana, Groyer, Harinala, Rosano, Giuseppe, Gaultney, Jennifer, Linden, Stephan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Original articles: Heart Failure
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481921/
https://www.ncbi.nlm.nih.gov/pubmed/37577867
http://dx.doi.org/10.2459/JCM.0000000000001532

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481921/
https://www.ncbi.nlm.nih.gov/pubmed/37577867
http://dx.doi.org/10.2459/JCM.0000000000001532

Ejemplares similares